Currently, the antibodies targeting the PD-1 and CTLA4 immune checkpoints have been successful in renal cell carcinoma (Bellone and Elia, 2017; Braun et al., 2021). This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.